SCHEMBL10004729

SCHEMBL10004729

Cc1nc2c(c(OC(C)C)c(C(=O)O)n2C)c(=O)n1-c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HKDC1 Q2TB90 2/20 0.53
▸ DRD1 P21728 3/20 0.42
▸ DRD5 P21918 3/20 0.42
▸ MAPK1 P28482 2/20 0.41
▸ GRM1 Q13255 3/20 0.41
▸ ALDH1A1 P00352 3/20 0.40
▸ RXFP1 Q9HBX9 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ KDR P35968 2/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC8 Q9BY41 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ POLB P06746 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ MAPT P10636 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ GRM5 P41594 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10004570 0.88 HKDC1 (0.48) HKDC1DRD1DRD5ALDH1A1SMN1; SMN2
SCHEMBL10003931 0.80 MAPT (0.40) MAPK1ALDH1A1LMNATSHRHTT
SCHEMBL10004630 0.78 SMO (0.46) HKDC1ALDH1A1POLBMAPTNPSR1
SCHEMBL10004957 0.75 LMNA (0.45) MAPK1ALDH1A1LMNASMN1; SMN2KDR
SCHEMBL10004013 0.74 BRPF1 (0.37) DRD1DRD5ALDH1A1MAPT
SCHEMBL10003938 0.74 ALDH1A1 (0.57) HKDC1MAPK1GRM1ALDH1A1SMN1; SMN2
SCHEMBL10004072 0.72 PDE1A (0.38) MAPK1LMNASMN1; SMN2
SCHEMBL10003130 0.71 BCL2 (0.38) ALDH1A1SMN1; SMN2TSHR
SCHEMBL10003785 0.71 ALDH1A1 (0.39) ALDH1A1LMNASMN1; SMN2POLBTSHR
SCHEMBL10004739 0.68 CCNE2 (0.34) ALDH1A1LMNAPOLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471793-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2016-10-05 — — EP disclosed
US-8614208-B2 Fused heterocyclic ring derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-12-24 — — US disclosed
US-20120214795-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-23 — — US disclosed
EP-2471793-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214795-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH HKDC1 2807/4885DRD1 3640/4885DRD5 2541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback